Tarsus Pharmaceuticals, Inc. (TARS) shares ended the last trading session 10.6% higher at $43.87. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 20.6% gain over the past four weeks.The sudden soaring of the stock price can be attributed to positive investor expectations regarding the financial performance of Tarsus’ only marketed product in the United States, Xdemvy, approved for demodex blepharitis. The company i ...

Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients' eyelids Demodex blepharitis is a significant eyelid disease that impacts approximately 25 million people in the U.S. – or 1 out of every 12 adults Media accompanying this announcement is available by clicking on this link IRVINE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and n ...

Group 1 - The company has a strong academic foundation with expertise in finance and medicine, enhancing its capabilities in the financial sector [1] - The firm specializes in income investing and biotech/pharma investing, leveraging nearly a decade of experience [2][3] - The organization focuses on identifying both short-term catalyst-driven opportunities and long-term investment strategies in the biotech sector [3] Group 2 - Subscribers receive regular portfolio trade alerts and have access to an interactive chat feature, promoting engagement and support [4] - The company has published a best-selling book on biotech investing and offers educational courses, further establishing its authority in the field [4] - The firm provides custom biotech analysis upon request, catering to specific investor needs [5]

IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat at the 2024 Wells Fargo Securities Healthcare Conference taking place in ...

Core Viewpoint - Tarsus Pharma has an FDA-approved treatment for Demodex blepharitis, with significant market potential and multiple late-stage assets in its pipeline, including formulations of its key molecule, lotilaner [3][4][11] Market Opportunity - An estimated 25 million Americans suffer from Demodex blepharitis, with Tarsus's XDEMVY being the first and only FDA-approved treatment, establishing it as the definitive standard of care [3][4] - The company sees a $1 billion opportunity in the initial addressable segment, with over 7 million patients identified in the U.S. [4] Pipeline Developments - Tarsus has three product candidates: TP-03 for Meibomian gland disease (MGD), TP-04 for rosacea, and TP-05 for Lyme disease, all in various stages of clinical trials [5] - TP-05 demonstrated a 97% efficacy in killing ticks within 24 hours, indicating potential as a preventive treatment for Lyme disease [5] - TP-03 showed statistically significant improvement in MGD in a phase 2 trial, with ongoing regulatory discussions with the FDA [5] Competitive Landscape - Tarsus faces competition in the demodex-related disease market, with other companies like Bausch + Lomb and Azura Ophthalmics developing treatments for MGD [6] Financial Overview - Tarsus has a market cap of approximately $977 million and a cash balance of $323 million, with revenues reported at $40.8 million [7] - The company has seen a significant increase in SG&A expenses, which rose to $58.8 million, primarily due to compensation and costs related to the commercial launch of XDEMVY [7] Intellectual Property - Tarsus licensed the intellectual property for lotilaner from Elanco Animal Health, with favorable terms that allow for a low-cost development pathway [8][9] - The associated patents for lotilaner are valid until approximately 2032, providing a limited timeframe for market exclusivity [9] Investment Outlook - With a market cap of around $1 billion and a target market also valued at $1 billion, Tarsus presents an attractive investment opportunity, bolstered by upcoming catalysts and strong data from its programs [11]

Tarsus Pharmaceuticals Second Quarter 2024 Financial Results Conference Call August 8, 2024 Today's Speakers Bobak Azamian, M.D., Ph.D. Chief Executive Officer and Chairman Aziz Mottiwala Chief Commercial Officer Jeff Farrow Chief Financial Officer and Chief Strategy Officer 2 2 © Tarsus Pharmaceuticals | For Investor Purposes Only Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor ...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Nakasone - Head, Investor Relations Bobby Azamian - Chairman and CEO Aziz Mottiwala - Chief Commercial Officer Jeff Farrow - Chief Financial Officer and CSO Sesha Neervannan - Chief Operating Officer Conference Call Participants Tim Lugo - William Blair Pavan Patel - BofA Dennis Kennedy - LifeSci Capital Talani Usman - Goldman Sachs Frank Brisebois - Oppenheimer Michaela Diverio - ...

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $1.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 10.20%. A quarter ago, it was expected that this company would post a loss of $1.15 per share when it actually produced a loss of $1.01, delivering a surprise of 12.17%. Over the last four quarters, the compa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to ____. Commission File Number: 001-39614 TARSUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 81-4717861 ...

Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements Generated $40.8 million in XDEMVY net product sales in the second quarter and $65.5 million year-to-date ® Delivered more than 37,000 bottles of XDEMVY to patients in the second quarter Delivered an exceptional gross-to-net discount of 44% reflecting strong payer coverage including commercial and Medicare payers Expanded sales force remains on-track to be fully deployed by the end of the third quarter 2024 ...